ClinicalTrials.gg
CompletedNCT00140725Updated Oct 16, 2008

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

A Phase 3 interventional study of Lamivudine plus Polyethylene glyco-interferon alfa-2b and Lamivudine in Chronic Hepatitis B, sponsored by GlaxoSmithKline. Completed at 1 site in Hong Kong. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-10-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing lamivudine in Hepatitis B, Chronic — none open to participants now, none under way, none of them phase 3. Lamivudine · Hepatitis B, Chronic.

Enrollment
8th of 18
160 · median 81
Started
2000
the only one that year
Phase 3
5 of 19
none open now
Registered
5th of 19
by date
Lead sponsor
1 of 19
GlaxoSmithKline

Among the 19 studies testing lamivudine in Hepatitis B, Chronic, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2000, is one of 5 in phase 3, and was the 5th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 19 studies testing lamivudine in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing lamivudine in Hepatitis B, Chronic as a file.
02

Study summary

This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • HBeAg-positive
  • chronic
  • Hepatitis B
  • lamivudine
  • seroconversion
  • Chronic Hepatitis B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Untreated chronic patients with evidence of HBV replication as documented by serum HNV-DNA positive within 3 months prior to entry and serum HBeAg positive at screening.
  • Documented presence of abnormal (ALT) (1.3 - 5X upper limit normal ()) within 1 month prior to entry and signs of compensated liver disease.

Exclusion criteria

Exclusion criteria:

  • Patients with any cause for liver disease other than chronic and evidence or history of decompensated liver disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants

Interventions

  • DrugLamivudine plus Polyethylene glyco-interferon alfa-2b
  • Also known as: Lamivudine plus Polyethylene glyco-interferon alfa-2b

06

What researchers measure

Primary outcomes

  1. Proportion of patients with HBeAg seroconversion to anti-HBe

Secondary outcomes

  1. Normalization of alanine aminotransferase (ALT)

  2. Undetectable HBV DNA

  3. Histologic improvement

  4. Tyrosine, methionine, aspartate, aspartate (YMDD) mutants among the viremic relapsers at the end of therapy and safety of treatment

07

Study locations

1 site
  • GSK Investigational Site
    Shatin, Hong Kong
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00140725
Lead sponsor
GlaxoSmithKline
First posted
Sep 1, 2005
Start date
Apr 2000
Last update
Oct 16, 2008

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamivudine

Start the discussion